JP2023532128A - 抗がん作用を有する化合物 - Google Patents

抗がん作用を有する化合物 Download PDF

Info

Publication number
JP2023532128A
JP2023532128A JP2022581398A JP2022581398A JP2023532128A JP 2023532128 A JP2023532128 A JP 2023532128A JP 2022581398 A JP2022581398 A JP 2022581398A JP 2022581398 A JP2022581398 A JP 2022581398A JP 2023532128 A JP2023532128 A JP 2023532128A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
alkynylene
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532128A5 (enExample
Inventor
ゼメル ギタイ、
ハーン キム、
ジェイムズ ケー． マーチン、
ジョセフ ピー． シーハン、
ジョシュア ディー． ラビノウィッツ、
シンチェン シュー、
コナー チェイン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of JP2023532128A publication Critical patent/JP2023532128A/ja
Publication of JP2023532128A5 publication Critical patent/JP2023532128A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2022581398A 2020-07-02 2021-07-01 抗がん作用を有する化合物 Pending JP2023532128A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047612P 2020-07-02 2020-07-02
US63/047,612 2020-07-02
PCT/US2021/040171 WO2022006447A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity

Publications (2)

Publication Number Publication Date
JP2023532128A true JP2023532128A (ja) 2023-07-26
JP2023532128A5 JP2023532128A5 (enExample) 2024-07-09

Family

ID=79314944

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022581398A Pending JP2023532128A (ja) 2020-07-02 2021-07-01 抗がん作用を有する化合物
JP2023524493A Pending JP2023535527A (ja) 2020-07-02 2021-07-01 抗菌活性を有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023524493A Pending JP2023535527A (ja) 2020-07-02 2021-07-01 抗菌活性を有する化合物

Country Status (7)

Country Link
US (2) US20230295164A1 (enExample)
EP (2) EP4175953A4 (enExample)
JP (2) JP2023532128A (enExample)
CN (2) CN115867354B (enExample)
AU (2) AU2021301264A1 (enExample)
CA (2) CA3183770A1 (enExample)
WO (2) WO2022006447A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024531898A (ja) * 2021-08-17 2024-09-03 サウスウエスト リサーチ インスティテュート コロナウイルスに対する阻害剤
US20260138981A1 (en) * 2022-10-07 2026-05-21 The Trustees Of Princeton University Dihydrofolate reductase inhibitors for anti-biotic resistant infections
CN118047780A (zh) * 2022-11-09 2024-05-17 中国医学科学院药物研究所 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用
CN119661535B (zh) * 2023-09-21 2026-03-20 中国医学科学院药物研究所 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用
WO2025195460A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 稠环衍生物
CN121013722A (zh) * 2024-03-22 2025-11-25 深圳湾实验室坪山生物医药研发转化中心 结核病的预防与治疗

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
US20140329840A1 (en) * 2013-05-06 2014-11-06 Georgia Tech Research Corporation Molecules with potent dhfr binding affinity and antibacterial activity
US20140378486A1 (en) * 2013-06-20 2014-12-25 Oregon Health & Science University Pyrroloquinazoline compounds
US20190201401A1 (en) * 2017-08-01 2019-07-04 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
WO2021035045A1 (en) * 2019-08-20 2021-02-25 City Of Hope Mettl16 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45427B1 (en) * 1976-07-09 1982-08-25 American Home Prod Pyrrold 3,2if quinazoline-1,3-diamine and related compounds
US7253177B2 (en) * 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
EP3143036B1 (en) * 2014-05-11 2023-08-02 Tel Hashomer Medical Research Infrastructure and Services Ltd. Par-1 based therapeutic conjugates and uses thereof
US20210161900A1 (en) * 2018-04-30 2021-06-03 Duke University Compositions and methods for the treatment of senescent tumor cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
US20140329840A1 (en) * 2013-05-06 2014-11-06 Georgia Tech Research Corporation Molecules with potent dhfr binding affinity and antibacterial activity
US20140378486A1 (en) * 2013-06-20 2014-12-25 Oregon Health & Science University Pyrroloquinazoline compounds
US20190201401A1 (en) * 2017-08-01 2019-07-04 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
WO2021035045A1 (en) * 2019-08-20 2021-02-25 City Of Hope Mettl16 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANTA MARIA, J. P. JR. ET AL.: "Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis", ACS CHEMICAL BIOLOGY, vol. 12, no. 9, JPN6026004321, 2017, pages 2448 - 2456, ISSN: 0005792952 *

Also Published As

Publication number Publication date
AU2021301264A1 (en) 2023-02-02
AU2021299504A1 (en) 2023-02-02
US20230295164A1 (en) 2023-09-21
EP4175953A4 (en) 2024-08-14
US20230242540A1 (en) 2023-08-03
CA3183770A1 (en) 2022-01-06
CA3183776A1 (en) 2022-01-06
WO2022006432A1 (en) 2022-01-06
CN115867354B (zh) 2025-08-26
WO2022006447A1 (en) 2022-01-06
JP2023535527A (ja) 2023-08-17
CN116234808B (zh) 2025-11-14
CN115867354A (zh) 2023-03-28
CN116234808A (zh) 2023-06-06
EP4175953A1 (en) 2023-05-10
EP4175958A4 (en) 2024-07-17
EP4175958A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
CN115867354B (zh) 具有抗癌活性的化合物
TW402582B (en) Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
AU2007257781B2 (en) Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
ES2293324T3 (es) Derivados de pteridina para el tratamiento de enfermedades relativas al tnf-alpha.
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
SK1842003A3 (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals
US20100266674A1 (en) L-oddc prodrugs for cancer
JP2018529770A (ja) Ｊａｋを阻害するための化合物及び方法
WO2023146960A1 (en) Parp1 inhibitors and uses thereof
RU2003137007A (ru) Новые пиридилцианогуанидиновые соединения
WO2013178576A1 (en) Acid ceramidase inhibitors and their use as medicaments
KR20200015515A (ko) 암, 망막 장애 및 심근증을 치료하기 위한 3중 치환된 피리미딘 화합물 및 조성물
WO2024074128A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20040111626A (ko) 시아노구아니딘 전구약물
CA2291489A1 (en) Cyanoguanidines as cell proliferation inhibitors
US20080176923A1 (en) Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors
JP4814245B2 (ja) 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ
CN103025722B (zh) 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性
WO1998054146A1 (en) Cyanoguanidines as cell proliferation inhibitors
JP7834842B2 (ja) 非対称ｇｐｒ８４拮抗剤およびその使用
EP1144423B1 (en) Bis-terpyridine-platinum(ii) complexes
RU2068843C1 (ru) 2-/3-(2-хлорэтил)-3-нитрозоуреидо/-1,3-пропандиол, обладающий противоопухолевой активностью
JPS59501110A (ja) 抗腫瘍活性を有する薬剤組成物
RU2768451C1 (ru) Селективный антагонист рецепторов типа A2A
HUP0300688A2 (hu) Bisz[N,N'-bisz(2-halogén-etil)-amino]-foszforamidát-származékok mint daganatellenes hatású hatóanyagok

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260804